Please ensure Javascript is enabled for purposes of website accessibility

J&J Accepts $4 Billion Carlyle Offer for Diagnostics Unit

By Associated Press – Mar 31, 2014 at 3:49AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ortho-Clinical business serves hospitals, testing laboratories and blood banks.

NEW BRUNSWICK, N.J. (AP) -- Johnson & Johnson has accepted an offer of about $4 billion from the private equity firm The Carlyle Group to buy its Ortho-Clinical Diagnostics business.

J&J said Monday that the deal for the blood-testing unit should close by mid-year.

The New Brunswick, N.J., health care giant had said in January that Washington, D.C.-based Carlyle Group had offered $4.15 billion for the business, and that it would talk to works councils and trade unions representing its employees before making a decision.

The Ortho-Clinical business serves hospitals, testing laboratories and blood banks. It supplies equipment and chemicals to screen donated blood for HIV, hepatitis C and other serious diseases. It also makes technology for advanced testing of blood to diagnose health conditions and to monitor medication effects.

Ortho Clinical Diagnostics is based in Raritan, N.J., and employs more than 4,500 employees. It runs factories in Rochester, N.Y.; Pompano Beach, Fla.; and Pencoed, Wales.

J&J CEO Alex Gorsky had said last year the company was looking at strategic options for Ortho-Clinical Diagnostics, which doesn't meet the company's long-held strategy of focusing on businesses that rank first or second in their markets.

Shares of J&J rose $0.55 to $97.99 on premarket trading Monday about an hour and a quarter before the markets opens. They have climbed more than 6% so far this year.

link

The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.